GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Uproleselan's failed Phase III AML trial shakes up GlycoMimetics' future [Yahoo! Finance]
GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at Capital One Financial Co. from an "overweight" rating to an "equal weight" rating.
GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate [Yahoo! Finance]